FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 Tepl...
Approval of teplizumab: implications for patients Type 1 diabetes mellitus (T1DM) can be predicted, and immune therapy can alter the progression of the disease. The FDA's approval of teplizumab as the first disease-modifying therapy for T1DM and the first therapy aimed at delaying the c.....
has led to the subsequent approval of at least 5 additional TNF inhibitors by the FDA. However, 20–30% of patients either do not respond to therapy or develop de novo autoimmune phenomena. The paradoxical exacerbation of lupus-like syndromes, demyelinating encephalopathy, and psoriasis in patients...
FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 Tepl...
FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 ...